Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zamto-Cel in Severe Refractory Autoimmune Diseases
NCT06708845Phase 1Recruiting
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Jul 2026
- Primary completion
- Jan 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of zamtocabtagene autoleucel in systemic lupus erythematosus (SLE), lupus nephritis (LN) and systemic sclerosis (SSc) (2 arms), sponsored by Miltenyi Biomedicine GmbH. Primary endpoints: Adverse Events at 12 months and Dose-Limiting Toxicities at 28 days. Started Jul 2026; status: recruiting.
02
Drugs
zamtocabtagene autoleucel
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06708845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06708845.